Colchicine attenuates kidney injury by modulating the NLRP3 inflammasome pathway Authors: Gyuri Kim, Ga Young Heo, Bo Young Nam, YooJin Cho, Je Wook Yu, Cheol Ho Park, Hyung Woo Kim, Jung Tak Park, Tae-Hyun Yoo, Shin-Wook Kang, Seung Hyeok Han Published: 2026 ABSTRACT AbstractBackgroundColchicine, a well-known anti-inflammatory drug, has emerged as a therapeutic option in various inflammatory diseases. However, its role in chronic kidney disease (CKD) remains unclear. This study aims to investigate the reno-protective effects of colchicine in an experimental CKD model and its potential role in modulating the NOD-like receptor, pyrin domain containing protein 3 (NLRP3) inflammasome pathway.MethodsA CKD animal model was established in C57BL/6 mice by feeding a 0.2% adenine-containing diet. Colchicine (0.3 mg/kg/day) or saline was administered intraperitoneally for 4 weeks. RNA sequencing of kidney tissue was performed to capture molecular signatures associated with the therapeutic mechanism of colchicine in CKD. In vitro, renal tubular epithelial cells (RTECs) were treated with transforming growth factor-β (TGF-β, 10 ng/ml) and bone marrow-derived macrophages (BMDMs) were exposed to p-cresol sulfate (PCS, 0.5 mM). Colchicine (0.1 μM for RTECs and 1.0 μM for BMDMs) was administered to evaluate its protective effects.ResultsColchicine treatment significantly reduced systemic inflammatory markers including tumor necrosis factor-α, interleukin-6, and interleukin-1β. In the kidney tissues of adenine-fed mice, prominent fibrotic change and macrophage infiltration were observed, both of which were significantly attenuated by colchicine treatment. These improvements were accompanied by reduced albuminuria and improved kidney function. RNA sequencing revealed that colchicine modulated key inflammatory pathways, including the nuclear factor-κB and NOD-like receptor signaling pathway. Notably, colchicine treatment significantly decreased the expression levels of NLRP3 inflammasome components in adenine-fed mice, TGF-β-treated RTECs and PCS-treated BMDMs. Mechanistically, colchicine inhibited the interaction between NLRP3 and apoptosis-associated speck-like protein containing a CARD in TGF-β-treated RTECs and PCS-treated BMDMs, resulting in decreased NLRP3 inflammasome assembly, as demonstrated by oligomerization cross-linking assay and proximity-ligation assay.ConclusionsWe demonstrated that colchicine can attenuate kidney injury and fibrosis in adenine-induced CKD mice by inhibiting NLRP3 inflammasome assembly and activation.Supplementary InformationThe online version contains supplementary material available at 10.1186/s10020-026-01511-7.Keywords: Colchicine, NLRP3 inflammasome, Chronic kidney disease, Inflammation, Fibrosis Introduction Globally, approximately 788 million adults aged ≥ 20 years have chronic kidney disease (CKD), representing a doubling since 1990, with CKD now ranking as the ninth leading cause of death and responsible for 1.48 million deaths annually (Francis et al. 2024; Mark et al. 2025). CKD is characterized by a progressive decline in kidney function, ultimately leading a substantial portion of patients to require kidney replacement therapy (Saran et al. 2019). Given the irreversible and progressive nature of CKD, it is crucial to identify effective therapeutic targets to prevent the progression of CKD. CKD is associated with a state of low-grade chronic inflammation (Gupta et al. 2012). Inflammation plays a critical role in the initiation and progression of kidney fibrosis, representing the final common pathological pathway in various CKD etiologies (Lv et al. 2018; Ruiz-Ortega et al. 2020). The inflammatory cascade in CKD can be triggered not only by pathogen-associated molecular patterns from external pathogens but also the danger-associated molecular patterns (DAMPs) released during cell damage and tissue injury (Rosin and Okusa 2011). DAMPs bind to pattern recognition receptors, which activate inflammatory pathways such as the activation of nuclear factor-κB (NF-κB) signaling pathway and the upregulation of genes such as tumor necrosis factor (Leemans et al. 2014; Rosin and Okusa 2011). Upon binding of DAMPs to pattern recognition receptors, the assembly of the NOD-like receptor, pyrin domain containing protein 3 (NLRP3) inflammasome is also triggered, facilitating the downstream cascade that promotes the conversion of pro‐interleukin-1β and prointerleukin-18 into their active forms, interleukin-1β (IL-1β) and interleukin-18 (IL-18). These cytokines contribute to the inflammatory response by recruitment of immune cells, while caspase-1 activation in the inflammasome complex leads to the formation of pores in the cell membrane and pyroptotic cell death, which further amplifies tissue damage (Mulay 2019; Schroder and Tschopp 2010). Furthermore, the dysregulated or prolonged inflammatory response activates resident fibroblasts and promotes extracellular matrix deposition, thereby accelerating interstitial fibrosis and irreversible nephron loss (Goligorsky 2008; Vilaysane et al. 2010). Therefore, the activation of the innate immune system and the resulting inflammatory response are key drivers of the pathological processes underlying kidney fibrosis. Colchicine exhibits potent anti-inflammatory properties that extend beyond its conventional use. Recent large-scale trials have demonstrated that low-dose colchicine significantly reduces cardiovascular risk, through the attenuation of inflammation associated with atherosclerosis (Nidorf et al. 2020; Tardif et al. 2019). Mechanistically, it inhibits microtubule polymerization, which impairs neutrophil and monocyte migration and chemotaxis (Asako et al. 1992; Cronstein et al. 1995; Hastie 1991; Phelps 2008). Additionally, colchicine disrupts intracellular transport pathways involving endosomes and exosomes (Asako et al. 1992; Cronstein et al. 1995) and suppresses the expression of E-selectin, an adhesion molecule, and reduces neutrophil superoxide synthesis (Chia et al. 2008). These actions collectively interfere with immune cell communication and dampen inflammatory signaling cascades. Notably, animal studies have demonstrated potential beneficial effects of colchicine in kidney disease models, including models of cyclosporine nephrotoxicity, unilateral ureteral obstruction, diabetic nephropathy, and hypertensive CKD (Disel et al. 2004; Guan et al. 2013; Li et al. 2009). However, it remains unclear whether colchicine confers a protective effect against renal inflammation in CKD models and which specific inflammatory pathways are involved, particularly in the context of CKD. Given colchicine’s well-established pharmacokinetic profile and emerging evidence of benefit in other chronic inflammatory diseases including cardiovascular disease, we aimed to investigate the reno-protective effect of colchicine in an experimental CKD model and explore its effects on inflammation through various pathways, focusing on elucidating the underlying mechanisms of colchicine treatment. Methods Animal study and treatment All animal experiments were conducted at Yonsei University College of Medicine (Seoul, Republic of Korea) in accordance with protocols approved by the Institutional Animal Care and Use Committee of Yonsei University College of Medicine (Approval No. 2023–0271). Six-week-old male C57BL/6 mice were purchased from Orient Bio, Inc. (Seoul, Republic of Korea) and acclimatized for one week prior to randomization. Male mice were used as they consistently develop more severe adenine-induced CKD compared to females, characterized by greater declines in kidney function, interstitial fibrosis, and tubular injury (Diwan et al. 2014; Metzger et al. 2021). These mice were randomly assigned to one of four groups: Control, control with colchicine treatment (CON + COL), CKD, and CKD with colchicine treatment (CKD + COL). CKD model was established by feeding a 0.2% adenine-containing diet (Jia et al. 2013), whereas control groups were fed a standard rodent diet. Colchicine (Sigma-Aldrich, St. Louis, MO, USA) was delivered intraperitoneally via an osmotic pump at a dose of 0.3 mg/kg/day for four weeks to the CON + COL and CKD + COL groups. The colchicine dose was selected with reference to prior murine studies demonstrating anti-inflammatory efficacy (Itano et al. 2017; Li et al. 2024; Weng et al. 2021), and our preliminary experiments confirming tolerability (Supplementary Fig. 1). Control and CKD groups received saline via an osmotic pump. Mice were sacrificed after four weeks on diets with and without colchicine treatment. Mice were anesthetized with Zoletil (Virbac, Carros, France; 10 mg/kg, intramuscular). 300–500 µL of blood samples were collected via cardiac puncture, followed by perfusion with normal saline. Kidneys were harvested, and euthanasia was completed by cardiac incision to ensure death. RNA-sequencing assay RNA sequencing was conducted using kidney tissue samples from four mice per experimental group (Control, CKD, and CKD + COL), and the resulting transcriptomic datasets were deposited in the NCBI Gene Expression Omnibus database (GSE318367) (Gyuri et al. 2026). The RNA-sequencing assay was conducted by E-Biogen Inc (Seoul, Korea), as described previously (Yin et al. 2021). Data mining and graphic visualization were performed using ExDEGA (Ebiogen Inc., Korea). Differentially expressed genes (DEGs) were analyzed based on a significance threshold with a fold change of ≥ 1.2 and a P-value of < 0.05. The identified genes were visualized in a heatmap. To evaluate the functions of the DEGs, gene ontology (GO) biological process and Kyoto encyclopedia of genes and genomes (KEGG) pathways were analyzed using Database for Annotation, Visualization and Integrated Discovery (DAVID). GO analyses also included cellular components, and molecular function categories using the DAVID FAT dataset. Gene set enrichment analysis (GSEA) was performed using the Molecular Signatures Database Hallmark gene sets to assess pathway-level changes. Enrichment results were quantified using normalized enrichment scores, and statistical significance was determined using false discovery rate. Primary tubular epithelial cell culture In this study, we used renal tubular epithelial cells (RTECs) as accumulating evidence suggests that NLRP3 inflammasome activation in tubular epithelial cells contributes significantly to CKD progression (Mulay 2019; Vilaysane et al. 2010). In addition, adenine-induced CKD model primarily causes tubulointerstitial damage through crystal-induced tubular toxicity and inflammation, making renal tubular epithelial cells the predominant site of injury. To this end, RTECs from C57BL/6 mice were cultured as described previously (Oh et al. 2018). Because transforming growth factor-β (TGF-β) is a well-established profibrotic cytokine that plays a central role in the development of tubulointerstitial fibrosis, and TGF-β stimulation induces epithelial injury, extracellular matrix production, and activation of inflammatory signaling pathways, primary RTECs were cultured with or without 10 ng/ml TGF-β (Sigma-Aldrich, MO, USA). To evaluate the protective effect of colchicine against TGF-β-induced kidney injury, RTECs were treated with 0.1 μM colchicine, a dose determined based on 3-(4,5-dimethylthiazol-2-yl)−2,5-diphenyltetrazolium bromide assay (MTT; Abcam, MA, USA) results (Supplementary Fig. 2 A). Cells were harvested for RNA and protein analyses after 48 h of stimulation. Bone marrow-derived macrophage cell culture Bone marrow cells were isolated from C57BL/6 mice and cultured in L929-conditioned medium, kindly provided by Prof. Je-Wook Yu, to differentiate into bone marrow-derived macrophages (BMDMs) (Fernandes-Alnemri et al. 2010). Both femurs and tibias were dissected, removing adherent soft tissue. Mouse bone marrow cells were extracted by flushing the femur and tibia with Dulbecco’s phosphate-buffered saline. The samples were centrifuged for 2 min at 1500 rpm, and the pellets were resuspended in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS and 100 U/ml penicillin and streptomycin. The samples were centrifuged for 2 min at 1500 rpm again. The pellets were resuspended and cultured in 8% L929-conditioned media. On day 4, the cultured medium was changed to 5% L929-conditioned media. After 2 additional days, adherent cells were detached using 0.25% trypsin–EDTA and plated in 6-well plates with complete DMEM containing 5% L929 conditioned media. BMDMs were incubated with 0.5 mM p-cresol sulfate (PCS) (Sigma-Aldrich, MO, USA) for 24 h, with and without 1.0 μM colchicine. We selected PCS as it is a representative uremic toxin that accumulates in CKD and is known to promote inflammatory activation, and oxidative stress. The dose of colchicine was determined based on the results of MTT assay (Supplementary Fig. 2B). Cells were then harvested for subsequent analyses. Total RNA extraction and reverse transcription Kidney samples were rapidly homogenized by mortar and pestle thrice with 700 μl of RNAiso reagent (Takara Bio Inc., Otsu, Shiga, Japan). For RTECs and BMDMs, 700 μl of RNAiso was added to the cell culture dish, and the suspension was collected and homogenized for 5 min at room temperature (RT). Following homogenization, 160 μl of chloroform was added to the homogenized samples and cells and shaken vigorously for 30 s. Samples were then stored for 3 min at RT and centrifuged at 12,000 rpm for 15 min at 4 °C. The aqueous phase was transferred to a new tube. RNA was precipitated with 500 μl of isopropanol, followed by centrifugation at 12,000 rpm for 30 min at 4 °C. The RNA pellet was washed with 70% ethanol, air-dried for 2 min, and then dissolved in sterile, diethyl pyrocarbonate-treated distilled water. Spectrophotometry was used to determine the concentration and quality of the extracted RNA at wavelengths of 260 and 280 nm. A Takara cDNA synthesis kit (Takara Bio Inc., Otsu, Shiga, Japan) was used to synthesize first-strand complementary DNA (cDNA) from extracted RNA. A total of 2 μg of RNA was reverse transcribed in a 10 μl of the reaction mixture containing 10 μM random hexanucleotide primer, 1 mM dNTP, 8 mM MgCl2, 30 mM KCl, 50 mM Tris–HCl at pH 8.5, 0.2 mM dithiothreitol, 25 U RNase inhibitor, and 40 U PrimeScript reverse transcriptase. The reaction mixture was incubated at 30 °C for 10 min, at 42 °C for 1 h, and at 99 °C for 5 min to inactivate the enzyme. Real-time quantitative polymerase chain reaction (qPCR) and western blot analyses Transcript levels were measured by qPCR. RNA quantification was performed using a NanoDrop spectrophotometer. A total of 1 μg of RNA was reverse transcribed using cDNA kit. qPCR was conducted in a 20 μL reaction mixture containing 10 μL SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA), 5 μL reverse transcribed cDNA, and 5 pM sense and antisense primers. The qPCR protocol included an initial denaturation step at 95 °C for 9 min, followed by 35 cycles of denaturation for 30 s at 94.5 °C, annealing for 30 s at 60 °C, and extension for 1 min at 72 °C. A final extension step was performed at 72 °C for 7 min. Each sample was run in triplicate, with a no-cDNA control run simultaneously. After real-time PCR, melting curve analysis was performed by gradually increasing the temperature from 60 to 95 °C at 2 °C per minute. The cDNA content in each sample was quantified using the comparative CT method (2-ΔΔCT). Genes related to fibrosis (Col1a1 and Fn1), macrophage infiltration (Adgre1 and Cd68), and the NLRP3 inflammasome pathway (Nlrp3, Pycard, Il18, and Il1b) were assessed in kidney tissue. In addition, NLRP3 inflammasome pathway related genes were examined in RTECs and BMDMs. Expression levels were normalized to 18S ribosomal RNA and expressed in arbitrary units. Primer sequences are listed in Supplementary Table 1. All primers were obtained from Applied Biosystems (Foster City, CA, USA). Western blot analysis was conducted to determine the protein expression levels of profibrotic markers and the NLRP3 inflammasome pathway. Protein extraction was carried out using a Bio-Rad kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Cultured cells and mouse kidney samples were lysed in sodium dodecyl sulfate (SDS) sample buffer [2% SDS, 10 mM Tris–HCl (pH 6.8), 10% (vol/vol) glycerol] and centrifuged at 10,000 g for 10 min at 4 °C. The supernatant was stored at −70 °C. Laemmli sample buffer was added to extract, containing 50 μg of protein, and the samples were boiled for 5 min and loaded onto acrylamide denaturing SDS–polyacrylamide gel. The separated proteins were transferred to a Hybond-ECL membrane using a Hoeffer semidry blotting apparatus (Hoeffer Instruments, San Francisco, CA, USA). The membrane was incubated in blocking buffer A (TBS, 0.1% Tween 20, and 5% nonfat milk) for 30 min at RT and incubated overnight at 4 °C with primary antibodies. The following antibodies were used: fibronectin (Abcam, Cambridge, MA, USA), type I collagen (Southern Biotech, Birmingham, AL, USA), NLRP3 (Cell Signaling Technology, Boston, MA, USA; and AdipoGen Life Sciences, San Diego, CA, USA), apoptosis-associated speck-like protein containing a CARD (ASC; Cell Signaling Technology, Boston, MA, USA), IL-1β (Thermo Fisher Scientific, Waltham, MA, USA) and IL-18 (Thermo Fisher Scientific, Waltham, MA, USA), and β-actin (Sigma-Aldrich, St. Louis, MO, USA). A horseradish peroxidase–conjugated anti-goat, anti–rabbit or anti–mouse IgG antibody (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used as secondary antibodies. After washing 3 times, the membranes were developed with chemiluminescent reagent (ECL, Amersham Life Science, UK). For experiments in which multiple target proteins were analyzed from the same set of samples, the same membrane was sequentially reprobed with different primary antibodies following appropriate stripping procedures. Accordingly, the same β-actin blot is shown as a loading control for proteins probed on the same membrane. The density of the bands was measured using ImageJ software ver. 1.49 (National Institutes of Health, Bethesda, MD, USA; online at http://rsbweb.nih.gov/ij). Assessment of inflammasome assembly ASC oligomerization in RTECs and BMDMs was assessed using a cross-linking assay. RTECs were treated with 10 ng/ml of TGF-β for 48 h, and mouse BMDMs were exposed to 0.5 mM of PCS for 24 h. The cells were lysed in 20 mM HEPES buffer (pH 7.5) containing 0.5% NP-40, 50 mM KCl, 1.5 mM MgCl2, 150 mM NaCl, 1 mM EGTA, and protease inhibitors, and centrifuged for 16,000 rpm at 10 min. Soluble lysates and insoluble pellets were separated by centrifugation. Pellets were resuspended in PBS containing 0.75 mM disuccinimidyl suberate (Thermo Scientific-Pierce, IL, USA). The cross-linked pellets and soluble lysates were fractionated on 12% SDS polyacrylamide gel and were simultaneously immunoblotted using anti-ASC antibody. To visualize the interaction of NLRP3 with ASC, a proximity-ligation assay (PLA) was also performed using the DuoLink PLA technology (Sigma-Aldrich, MO, USA) (Söderberg et al. 2006). RTECs and BMDMs were permeabilized with 0.25% Triton-X 100, blocked with Duolink blocking solution and incubated in a heated humidity chamber. Primary mouse anti-NLRP3 and rabbit anti-ASC antibodies were added and incubated for overnight at 4 °C. After three washes with buffer A, cells were incubated with Plus and Minus probes (antibodies conjugated to complementary oligonucleotide strands) for 1 h at 37 °C, ligated, and polymerized by DNA polymerase. The coverslips were washed with buffer B and mounted using a minimal volume of Duolink In Situ Mounting Medium with DAPI. Cells were then observed using a Zeiss LSM 510 Meta confocal microscope and analyzed with ImageJ to calculate the number of PLA particles in the nucleus. Histological and Immunohistochemical staining Paraffin-embedded kidney tissue samples were sliced into 5 µm thick sections for Periodic Acid-Schiff staining and Masson's trichrome staining for routine histological examination. The area of interstitial fibrosis was assessed on Masson’s trichrome-stained slides. In brief, images of five random fields were obtained, and staining was quantified as percentage of total area using ImageJ software with Color Deconvolution2 plug-in (Landini et al. 2021). For immunohistochemical staining, the tissue slices were deparaffinized, hydrated in ethyl alcohol, and washed in tap water. Antigen retrieval was conducted in citrate buffer (pH 6.0) by microwaving. The slices were blocked with donkey serum for 60 min at RT and incubated overnight at 4 °C with primary antibodies: anti-F4/80 (1:100, AdipoGen Life Sciences, San Diego, CA, USA), anti-CD68 (1:100, AdipoGen Life Sciences, San Diego, CA, USA) and anti-NLRP3 antibodies (1:100, Thermo Fisher Scientific, Waltham, MA, USA). Following washes, sections were incubated with horseradish peroxidase-conjugated secondary antibodies. Visualization was achieved using 3,3-diaminobenzidine with the Dako Envision Kit (Dako, Santa Clara, CA, USA). Staining was quantified as a percentage of the total area in images of five random fields using the ImageJ Color Deconvolution2 plug-in, which deconvolutes the image colors using the preset color vector and calculates the percentage of the positive area (Landini et al. 2021). Biochemistry Serum creatinine was assessed using a commercially available kit (Roche, Mannheim, Baden Württemberg, Germany) to evaluate kidney function. Urine albumin to creatinine ratio was calculated to quantify albuminuria (HITACHI, Tokyo, Japan). To examine the hepatotoxicity, alanine aminotransferase and aspartate aminotransferase (Roche, Mannheim, Baden Württemberg, Germany) were measured. Serum levels of inflammatory markers, including IL-1β, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were measured using a commercial multiplex kit (Millipore, Merck, Darmstadt, Germany). Statistical analysis Statistical analysis was conducted using GraphPad Prism 9.0 (GraphPad, San Diego, CA, USA). A student's t-test was conducted to compare the two groups. For comparison among more than three groups, a one-way analysis of variance was performed, followed by the post hoc Tukey test. A P-value less than 0.05 was considered statistically significant. Results Colchicine treatment attenuates systemic inflammation in CKD mice To confirm its systemic anti-inflammatory effects in a CKD animal model, the levels of pro-inflammatory cytokines were assessed. Circulating levels of TNF-α, IL-6, and IL-1β were significantly elevated in CKD mice compared to controls. Colchicine treatment significantly reduced the levels of these inflammatory cytokines, indicating that colchicine can attenuate systemic inflammation in CKD (Supplementary Fig. 3A-C). The 0.3 mg/kg dose of colchicine was well-tolerated in this experiment. None of the animals exhibited signs of diarrhea or dehydration and remained in good condition until sacrifice. Furthermore, hepatotoxicity analysis revealed no significant difference between groups (Supplementary Fig. 3D and E). Colchicine treatment attenuates renal fibrosis and improves kidney function in CKD mice Building on its systemic anti-inflammatory effects, we next investigated whether colchicine could protect against kidney fibrosis. As anticipated, CKD mice fed an adenine diet exhibited severe architectural disruption, characterized by prominent fibrotic changes such as tubular dilatation and degeneration, and interstitial widening with matrix accumulation. Consistent with the model's predominant pathology of crystal-induced tubular toxicity, glomeruli remained relatively preserved without significant structural changes. These pathological alterations were significantly attenuated by colchicine treatment (Fig. 1A). Consistent with these morphological improvements, Masson’s trichrome staining also revealed a significant reduction in the fibrotic area in colchicine-treated CKD mice (Fig. 1B). At the molecular level, colchicine treatment effectively reduced the elevated transcript levels of profibrotic genes, such as Fn1 (encoding fibronectin) and Col1a1 (encoding type I collagen), observed in CKD mice (Fig. 1C). Western blot analysis further confirmed a reduction in fibrotic protein expression following colchicine treatment (Fig. 1D). Consistent with the in vivo findings, the antifibrotic potential of colchicine was further evaluated in cultured RTECs. In TGF-β-treated RTECs, the mRNA and protein expression of profibrotic markers, including fibronectin and type I collagen was significantly elevated compared to controls. Colchicine treatment markedly reduced these levels (Supplementary Fig. 4 A and B). Colchicine attenuates renal fibrosis and improves kidney function in adenine-induced CKD mice. CKD was induced in male C57BL/6 mice by feeding an adenine-containing diet for 4 weeks, with administration of saline or colchicine (0.3 mg/kg/day) via an osmotic pump. A, B Representative kidney sections stained with Periodic acid–Schiff and Masson’s trichrome (scale bars = 100 μm). Fibrotic area was quantified as the percentage of Masson’s trichrome–positive area relative to the total tissue area. Masson’s trichrome staining showed reduced tubulointerstitial fibrosis in colchicine-treated CKD mice. C Relative mRNA expression levels of pro-fibrotic genes (Fn1 and Col1a1), normalized to 18S ribosomal RNA were decreased in colchicine-treated CKD mice. D Protein expression levels of fibronectin and collagen I, normalized to β-actin, were decreased in colchicine-treated CKD mice. E Serum creatinine levels, and F urinary albumin excretion, expressed as the urinary albumin to creatinine ratio were reduced in colchicine-treated CKD mice. Data are presented as means ± SEM. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. *, P < 0.05 vs. CON; #, P < 0.05 vs. CKD. Abbreviations: CON, control; CON + COL, control with colchicine treatment; CKD, chronic kidney disease; CKD + COL, chronic kidney disease with colchicine treatment; BUN, blood urea nitrogen; UACR, urinary albumin to creatinine ratio This attenuation of renal fibrosis translated into functional improvements. CKD mice fed an adenine diet displayed significantly elevated serum creatinine levels compared to controls, indicating impaired kidney function. However, these elevated levels were significantly decreased with colchicine treatment (Fig. 1E). Additionally, urinary albumin excretion, which was significantly higher in CKD mice compared to controls, was notably reduced by colchicine treatment (Fig. 1F). Together, these findings suggest that colchicine mitigates kidney fibrosis and restores kidney function in adenine-induced CKD mice. Transcriptomic analysis reveals therapeutic mechanisms of colchicine in CKD To elucidate the underlying therapeutic mechanisms of colchicine in CKD, RNA sequencing was performed on kidney tissues from control, CKD, and CKD + COL groups. Before DEG analysis, principal component analysis (PCA) was conducted to assess the similarities in expression patterns. The PCA plot revealed distinct clustering of gene expression profiles among the three groups (Supplementary Fig. 5). A total of 1,546 DEGs were identified with differential expression patterns observed between CKD vs. control and CKD + COL vs. CKD (Supplementary Fig. 6 A). Of these, 564 DEGs were down-regulated in CKD compared to control, but up-regulated following colchicine treatment. Conversely, 982 DEGs were up-regulated in CKD compared to controls, but down-regulated in colchicine-treated CKD group (Supplementary Fig. 6B and C). Pathway enrichment analyses provided insights into signaling pathways and the biological processes modulated by colchicine. The top 20 pathways are depicted. KEGG enrichment analysis indicated significant enrichment of pathways associated with extracellular matrix deposition, PI3K-Akt, and actin cytoskeleton regulation. Furthermore, KEGG enrichment analysis revealed the involvement of multiple inflammatory signaling pathways, such as the NF-κB pathway, NOD-like receptor signaling pathway, and cytokine-cytokine receptor interactions (Fig. 2A). GSEA further supported the enrichment of inflammatory signaling pathways in CKD, including inflammatory response, TNFα signaling via NF-κB, IL6–JAK–STAT3 signaling, and TGF-β signaling, whereas these enrichments were attenuated in colchicine-treated CKD mice (Supplementary Fig. 7). Biological process analysis highlighted the enrichment of pathways related to apoptotic processes, inflammatory response, and innate immune response (Fig. 2B). Additional GO analysis revealed enrichment of cellular components associated with membrane and vesicular structures, and molecular functions related to receptor activity and binding processes, which are consistent with signaling-related pathways observed in this study (Supplementary Fig. 8). A heatmap confirmed distinct expression patterns in the innate immune response category across the groups (Fig. 3A). A scatter plot further highlighted the downregulation of key NLRP3 inflammasome-related genes in CKD following colchicine treatment, including key NLRP3 inflammasome pathway-related genes such as Il6, Il1b, and Nlrp3 (Fig. 3B). Relative transcript levels of Nlrp3, Il1b, Nfkb1, and Tlr family genes were decreased in CKD mice with colchicine (Fig. 3C). These findings prompted further investigation into the activation of NLRP3 inflammasome pathway in CKD and its modulation by colchicine treatment. The KEGG pathways and biological processes enriched by DEGs counter-regulated by colchicine in CKD. DEGs were defined as genes with a fold change threshold of ≥ 1.2 and a p-value of < 0.05. Counter-regulated DEGs were defined as genes showing opposite expression patterns between these comparisons (i.e., upregulated in CKD vs. CON and downregulated in CKD + COL vs. CKD, or vice versa). A KEGG pathway enrichment analysis of counter-regulated DEGs. B Gene Ontology biological process enrichment analysis of counter-regulated DEGs. Enrichment analysis was performed using DAVID, and statistical significance was determined using Benjamini–Hochberg correction for multiple testing. The x-axis represents fold enrichment. The y-axis indicates the enriched pathways or biological process terms. Dot size represents the number of DEGs. Dot color indicates statistical significance as − log10(q-value), where q-values are adjusted P-values; higher values (blue) indicate more significant enrichment. Abbreviations: CON, control; CKD, chronic kidney disease; CKD + COL, chronic kidney disease with colchicine treatment; KEGG, Kyoto Encyclopedia of Genes and Genomes; DEG, differentially expressed gene Colchicine modulates the innate immune response–related gene expression in CKD mice. RNA sequencing was performed on kidney tissues from CON, CKD, and CKD + COL mice. DEGs were defined as genes with a fold change ≥ 1.2 and P < 0.05. A Heatmap showing expression patterns of innate immune response–related DEGs across CON, CKD, and CKD + COL groups. Gene expression values were normalized and scaled (z-score) across samples. B Scatter plot comparing gene expression levels between CKD and CKD + COL groups within innate immune response–related DEGs. Each dot represents a gene. C Relative mRNA expression levels of representative innate immune–related genes were measured by quantitative real-time PCR and expressed relative to control. Data are presented as means ± SEM. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. *, P < 0.05 vs. CON; #, P < 0.05 vs. CKD. Abbreviations: CON, control; CKD, chronic kidney disease; CKD + COL, chronic kidney disease with colchicine treatment; DEG, differentially expressed gene Colchicine treatment reduces proinflammatory macrophage infiltration in CKD mice Given the anti-inflammatory signatures of colchicine effects observed from the unbiased transcriptomic analysis, we explored macrophage infiltration, a key driver of inflammation, in the kidneys of CKD mice. CKD mice exhibited significantly higher levels of mRNA and protein expression of macrophage markers, including F4/80 (encoded by Adgre1) and CD68, compared to the control group, indicating increased macrophage infiltration. Colchicine treatment significantly reduced these markers (Fig. 4A and B). Immunohistochemistry analysis further confirmed a reduction in the percentage of F4/80- and CD68-positive areas in the tubulointerstitial space of colchicine-treated CKD mice (Fig. 4C and D). Because macrophage-driven inflammation is tightly linked to the generation of reactive oxygen species and tissue oxidative stress, we also assessed oxidative injury in the kidney. Notably, colchicine-treated CKD mice showed a marked reduction in oxidative stress, as indicated by a reduced percentage of 4-HNE–positive area in the kidney (Fig. 4E). Colchicine reduces renal macrophage infiltration and oxidative stress in adenine-induced CKD mice. A Relative mRNA expression levels of macrophage-related genes (Arg1 and Cd68), normalized to 18S ribosomal RNA, were decreased in colchicine-treated CKD mice. B Protein expression levels of macrophage markers (CD68 and F4/80), normalized to β-actin, were decreased in colchicine-treated CKD mice. Representative immunohistochemical staining and quantification of C F4/80-positive area, D CD68-positive area, and E 4-HNE-positive area in kidney tissue (scale bars = 100 μm). Data are presented as means ± SEM. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. *, P < 0.05 vs. CON; #, P < 0.05 vs. CKD. Abbreviations: CON, control; CON + COL, control with colchicine treatment; CKD, chronic kidney disease; CKD + COL, chronic kidney disease with colchicine treatment; mRNA, messenger ribonucleic acid; 4-HNE, 4-hydroxynonenal Colchicine attenuates the renal activity of the NLRP3 inflammasome pathway in CKD mice As genes involved in NOD-like receptor signaling pathway were distinctly expressed across the groups in the transcriptomic analysis, the role of the NLRP3 inflammasome pathway in CKD mice with and without colchicine treatment were examined. The mRNA and protein expression levels of key NLRP3 inflammasome components, including NLRP3 and ASC (encoded by Pycard), as well as the final products of the pathway such as IL-1β and IL-18, were significantly increased in the kidneys of CKD mice compared to controls. Conversely, colchicine treatment effectively reduced the elevated expression levels of these components (Fig. 5A and B). To further assess NLRP3 inflammasome activation, the protein expression levels of pro-caspase-1 and cleaved caspase-1 were measured. Notably, colchicine treatment reduced the elevated caspase-1 cleavage in CKD kidneys, indicating suppression of NLRP3 inflammasome activation (Fig. 5C). Immunohistochemistry analysis corroborated these findings. The percentage of NLRP3-positive area was markedly increased in the kidneys of CKD mice, which was significantly decreased by colchicine treatment (Fig. 5D). Colchicine attenuates renal NLRP3 inflammasome activation in adenine-induced CKD mice. A Relative mRNA expression levels of NLRP3 inflammasome components (Nlrp3 and Pycard) and inflammasome-associated cytokines (Il1b and Il18), normalized to 18S ribosomal RNA, were decreased in colchicine-treated CKD mice. B Protein expression levels of NLRP3 inflammasome components (NLRP3 and ASC) and cytokines (IL-1β and IL-18), normalized to β-actin, were decreased in colchicine-treated CKD mice. C Protein expression of pro-caspase-1 and cleaved caspase-1 (p20), with reduced cleaved caspase-1 levels in colchicine-treated CKD mice. D Representative immunohistochemical staining and quantification of NLRP3-positive area in kidney tissue (scale bars = 100 μm). Data are presented as mean ± SEM. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. *P < 0.05 vs. CON; #P < 0.05 vs. CKD. Abbreviations: CON, control; CON + COL, control with colchicine treatment; CKD, chronic kidney disease; CKD + COL, chronic kidney disease with colchicine treatment; NLRP3, NOD-like receptor, pyrin domain containing protein 3; ASC, Apoptosis-associated speck-like protein containing a CARD; IL-18, interleukin-18; IL-1β, interleukin-1 beta; mRNA, messenger ribonucleic acid Colchicine suppresses profibrotic markers, NLRP3 inflammasome activity and assembly in RTECs and BMDMs To further investigate the inhibitory effects of colchicine on the NLRP3 inflammasome pathway, we examined its activity and assembly in both RTECs and BMDMs. Colchicine significantly decreased the mRNA and protein levels of NLRP3 inflammasome components (Nlrp3 and Pycard) and downstream effectors (Il18 and Il1b) in RTECs (Fig. 6A and B). Similar results were observed in BMDMs subjected to uremic conditions induced by PCS treatment. The mRNA and protein levels of NLRP3 inflammasome-related components (NLRP3, ASC, IL-1β, and IL-18) were elevated compared to the control. These expression levels were notably reduced by colchicine (Fig. 6C and D). Given that NLRP3 oligomerizes with the adapter protein ASC to form the NLRP3 inflammasome complex, we next examined whether colchicine affects this assembly. In the ASC oligomerization cross-linking assay, oligomerized ASC was markedly increased in both TGF-β-treated RTECs and PCS-treated BMDMs compared to controls. Colchicine treatment showed a clear tendency to reduce ASC oligomerization in both cell types (Fig. 6E and F). To further validate these findings, we performed a PLA. Consistent with the cross-linking results, ASC-NLRP3 proximity was clearly observed in TGF-β-treated RTECs as well as in PCS-treated BMDMs, but this interaction was markedly reduced following colchicine treatment (Fig. 6G and H). Colchicine attenuates NLRP3 inflammasome activation in RTECs and BMDMs. Primary RTECs were stimulated with 10 ng/ml TGF-β and treated with 0.1 μM colchicine for 48 h, while BMDMs were stimulated with 0.5 mM PCS and treated with 1.0 μM colchicine for 24 h. A, B In RTECs, mRNA and protein expression levels of NLRP3 inflammasome components and associated cytokines were increased by TGF-β stimulation and reduced by colchicine treatment. The β-actin blot presented in this figure is identical to that shown in Supplementary Fig. 4B, as target proteins were analyzed on the same membrane and shared a common β-actin loading control. C, D In BMDMs, PCS-induced increases in mRNA and protein expression levels of NLRP3 inflammasome components and associated cytokines are attenuated by colchicine treatment. E, F ASC oligomerization, assessed by cross-linking assay, was increased by TGF-β in RTECs and by PCS in BMDMs, and was reduced by colchicine treatment. G, H Interaction between NLRP3 and ASC, assessed by proximity ligation assay, was increased in TGF-β–treated RTECs and PCS-treated BMDMs and was attenuated by colchicine treatment (scale bars = 250 μm). Data are presented as means ± SEM. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. *, P < 0.05 vs. CON; #, P < 0.05 vs. TGF-β–treated RTECs or PCS-treated BMDMs. Abbreviations: RTECs, renal tubular epithelial cells; BMDMs, bone marrow–derived macrophages; CON, control; CON + COL, control with colchicine treatment; TGF-β, transforming growth factor-beta1; TGF-β + COL, TGF-β–treated RTECs with colchicine treatment; PCS, p-cresol sulfate; PCS + COL, PCS-stimulated BMDMs with colchicine treatment; NOD-like receptor, pyrin domain containing protein 3; ASC, apoptosis-associated speck-like protein containing a CARD; IL-18, interleukin-18; IL-1β, interleukin-1 beta; mRNA, messenger ribonucleic acid Discussion This study demonstrated that colchicine treatment attenuated the activation of the NLRP3 inflammasome pathway in animal models of kidney injury, as well as in RTECs and BMDMs under uremic conditions. Although previous studies have suggested reno-protective or anti-inflammatory effects of colchicine in various kidney injury models, those studies did not directly investigate NLRP3 inflammasome assembly in renal tissue. In contrast, our study provides mechanistic evidence that colchicine suppresses NLRP3 inflammasome activation by inhibiting NLRP3–ASC interaction and ASC oligomerization in both RTECs and macrophages. This was further confirmed by proximity ligation assay. Suppression of the NLRP3 pathway led to a reduction in systemic inflammation and macrophage infiltration, ultimately mitigating cell injury and fibrosis in the kidney. These findings provide new insights into the therapeutic potential of colchicine in CKD by elucidating its mechanism of action. A schematic illustration summarizing the mechanisms underlying the protective effects of colchicine in CKD is provided in Fig. 7. Graphical illustration of the proposed molecular mechanisms responsible for the beneficial effects of colchicine. Abbreviations: CKD, chronic kidney disease; PAMPs, pathogen-associated molecular patterns; DAMPs, damage-associated molecular patterns; TLR, toll-like receptor; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NLRP3, NOD-like receptor, pyrin domain containing protein 3; ASC, apoptosis-associated speck-like protein containing a CARD; IL-18, interleukin-18; IL-1β, interleukin-1 beta; mRNA, messenger ribonucleic acid Chronic inflammation is increasingly recognized as a central driver of CKD progression, contributing to both structural damage and functional decline of the kidney (Fried et al. 2004; Remuzzi et al. 2005; Tonelli et al. 2005). Beyond its role as a consequence of injury, inflammation actively promotes fibrotic remodeling, tubular cell injury, and interstitial expansion, all of which culminate in irreversible nephron loss (Duffield 2014; Ferenbach and Bonventre 2015). A variety of endogenous and exogenous stimuli, including uremic toxins, oxidative stress, and metabolic disturbances, activate innate immune responses in the kidney (Kurts et al. 2013). Among these, the NLRP3 inflammasome has emerged as a key molecular platform linking cellular injury to inflammation and fibrosis. NLRP3 inflammasome has been suggested as a potential contributor to inflammation and fibrosis in various kidney injury models (Krishnan et al. 2019; Shahzad et al. 2015; Zheng et al. 2021). In a diabetic nephropathy mouse model, an increase in serum levels of IL-1β and IL-18 was observed prior to the onset of albuminuria and histological damage, suggesting early systemic activation of the NLRP3 inflammasome (Shahzad et al. 2015). Similarly, in hypertensive mouse models, the inhibition of the NLRP3 inflammasome has been demonstrated to alleviate kidney inflammation, fibrosis, and dysfunction (Krishnan et al. 2019). Moreover, mice lacking the Nlrp3 gene exhibited reduced tubular apoptosis, inflammation, and fibrosis, along with suppressed leukocyte recruitment and inflammatory cytokines following the unilateral ureteral obstruction (Vilaysane et al. 2010). Conversely, inhibition of inflammasome components, particularly NLRP3 and its downstream cytokines, such as IL-18, IL-1β, has demonstrated significant protective effects against tubular damage and interstitial fibrosis (Bani-Hani et al. 2009; Ludwig-Portugall et al. 2016). In line with these findings, we showed the activation of the NLRP3 inflammasome in an adenine-induced CKD mouse model, as evidenced by increased renal expression of NLRP3, ASC, IL-1β, and IL-18. Notably, this was accompanied by macrophage infiltration in the tubulointerstitial space, as demonstrated by increased F4/80 and CD68 expression. While NLRP3 inflammasome is typically attributed to macrophages, the findings of our study revealed that the expression levels of NLRP3 inflammasome pathway components were also markedly increased in tubular compartments of CKD mouse kidneys and TGF-β-treated RTECs. These results suggest that both immune and kidney parenchymal cells contribute to inflammasome-mediated kidney injury in CKD. One of the notable findings of our study is the elucidation of the specific mechanisms underlying kidney-protective effects of colchicine in a murine CKD model. It was clearly shown that colchicine inhibits the NLRP3 inflammasome pathway, thereby reducing kidney inflammation and fibrosis in CKD. In adenine-fed CKD mice, colchicine treatment significantly attenuated the expression of key inflammasome components, including NLRP3, ASC, IL-1β, and IL-18, in kidney tissue, along with a reduction in systemic proinflammatory cytokines. These effects were recapitulated in vitro in both TGF-β-treated RTECs and PCS-treated BMDMs, indicating that colchicine exerts consistent anti-inflammatory effects across both immune and parenchymal cell types. Mechanistically, oligomerization cross-linking assays and PLA revealed that colchicine inhibited the interaction between NLRP3 and its adaptor protein ASC, a critical step for inflammasome assembly and downstream cytokine maturation. These findings support the hypothesis that colchicine interferes with protein–protein interactions required for inflammasome complex formation, likely through its known action on microtubule dynamics. Additionally, colchicine reduced macrophage infiltration in the kidney, as evidenced by decreased expression of F4/80 and CD68 and reduced interstitial accumulation of these immune cells. Taken together, these findings suggest that colchicine not only suppresses the NLRP3 inflammasome activation at the molecular level but also mitigates immune cell recruitment and sustained tissue injury. Overall, our study highlights colchicine’s potential as a therapeutic agent to target inflammasome-driven inflammation and tissue fibrosis in CKD, providing a promising strategy to slow the progression of CKD. A major strength of this study lies in the use of transcriptomic analysis to explore the potential therapeutic mechanisms of colchicine in an experimental CKD model. RNA sequencing identified significant alterations in multiple biological pathways related to inflammatory responses, immune regulation, and fibrosis, all of which are hallmarks of CKD. Specifically, colchicine downregulated pathways involved in extracellular matrix accumulation and cytoskeleton organization, and inflammatory signaling, including NF-κB, NOD-like receptor, and cytokine–cytokine receptor interaction pathways. Consistently, transcript levels of key pro-inflammatory mediators, including Nlrp3, Il1b, and Nfkb1, were significantly reduced following colchicine treatment. Importantly, our study extends beyond prior reports describing the anti-inflammatory effects of colchicine by providing mechanistic evidence that colchicine suppresses NLRP3 inflammasome assembly in kidney disease. We demonstrated that colchicine inhibits ASC oligomerization and disrupts the NLRP3–ASC interaction in both renal tubular epithelial cells and macrophages, identifying inflammasome complex assembly as a specific molecular target of colchicine in CKD. Furthermore, the consistent inhibitory effects observed in both renal tubular epithelial cells and macrophages suggest that colchicine modulates inflammasome-driven inflammation in both kidney parenchymal and immune cells. Given its established clinical use and safety profile, these findings support the potential repurposing of colchicine as a therapeutic strategy targeting inflammasome-driven inflammation in CKD. However, further studies are needed to evaluate its long-term safety, optimal dosing, and efficacy in CKD patients. Despite its strengths, several limitations should be acknowledged. First, while the present study focused on the adenine-induced model of CKD, which mimics tubulointerstitial injury and fibrosis, it does not encompass the full spectrum of CKD etiologies. However, our previous work has demonstrated the protective effects of colchicine in a diabetic nephropathy model (Li et al. 2009), supporting the notion that colchicine may exert beneficial effects across different types of kidney injury. Nonetheless, additional studies in other models are warranted to further validate its broad applicability. Second, although preliminary dose-ranging experiments were conducted, the present study primarily evaluated colchicine at a single dose (0.3 mg/kg/day) and treatment duration. While we demonstrated that this dose was well tolerated, with no evidence of liver toxicity, no apparent gastrointestinal side effects, and relatively good survival throughout the study period, further studies are needed to assess long-term safety, define an optimal dosing range, and evaluate potential off-target effects. This is particularly important given colchicine’s narrow therapeutic index and known toxicity risks at higher doses in clinical use. Third, although our study demonstrated suppression of NLRP3 inflammasome assembly through protein-level assays, including ASC oligomerization cross-linking and proximity ligation analyses, additional genetic approaches such as siRNA-mediated knockdown of key inflammasome components would further strengthen causal inference regarding the specific molecular pathways involved. Fourth, upstream regulators of NLRP3 activation, such as ceramide signaling and TXNIP–NLRP3 interaction, have recently been implicated in inflammasome activation and kidney injury (Datta et al. 2025). Whether colchicine modulates these pathways remains to be determined and warrants further investigation. Lastly, while transcriptomic analysis provided mechanistic insight into the molecular actions of colchicine, additional proteomic and pathway-targeted validation would strengthen the interpretation of these findings. Conclusions In this study, we demonstrated that colchicine treatment effectively attenuates activation of the NLRP3 inflammasome pathway in multiple models of kidney injury, including TGF-β-treated RTECs, PCS-treated BMDMs, and an adenine-induced CKD mouse model. Colchicine inhibited the assembly of the NLRP3 inflammasome complex, suppressed the expression of key inflammatory mediators, and reduced macrophage infiltration into the kidney. These molecular and cellular effects were associated with significant reductions in tubular injury and interstitial fibrosis. Collectively, these findings suggest that colchicine mitigates tubulointerstitial kidney injury by targeting inflammasome-driven inflammation and tissue remodeling, highlighting its potential as a therapeutic strategy to slow CKD progression. Further studies in additional CKD models and clinical settings are warranted to confirm its broader applicability. Supplementary Information Supplementary Material 1. Acknowledgements We thank Medical Illustration & Design, a part of the Medical Research Support Services of Yonsei University College of Medicine, for providing excellent support with medical illustration. Abbreviations Apoptosis-associated speck-like protein containing a CARD Bone marrow–derived macrophage Complementary DNA Chronic kidney disease Colchicine Damage-associated molecular pattern Database for Annotation, Visualization and Integrated Discovery Differentially expressed gene Dulbecco’s modified Eagle’s medium Gene ontology Gene set enrichment analysis Interleukin-1β Interleukin-6 Interleukin-18 Kyoto Encyclopedia of Genes and Genomes Nuclear factor κB NOD-like receptor, pyrin domain containing protein 3 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay Principal component analysis P-cresol sulfate Proximity-ligation assay Quantitative polymerase chain reaction Renal tubular epithelial cell Room temperature Sodium dodecyl sulfate Transforming growth factor-β Tumor necrosis factor-α Authors’ contributions SHH conceived and supervised the project and designed the experiments. GK, GYH, BYN, and YJC performed the experiments and interpreted the data. GK, GYH, and SHH wrote the manuscript. JWY, CHP, HWK, JTP, THY, and S-WK critically reviewed the manuscript. All authors approved the final version of the manuscript. Funding This study was supported by an internal research grant from the Department of Internal Medicine, Yonsei University College of Medicine. Data availability The data supporting the findings of the present study are available from the corresponding author upon reasonable request. The transcriptomic data generated for this study have been deposited in the NCBI Gene Expression Omnibus (GEO) database under the accession number GSE318367. Declarations Ethics approval and consent to participate All animal experiments were conducted at Yonsei University College of Medicine (Seoul, Republic of Korea) in accordance with the relevant institutional guidelines and were approved by the Institutional Animal Care and Use Committee (IACUC) of Yonsei University College of Medicine (Approval No. 2023–0271). Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Gyuri Kim and Ga Young Heo contributed equally to this work. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The data supporting the findings of the present study are available from the corresponding author upon reasonable request. The transcriptomic data generated for this study have been deposited in the NCBI Gene Expression Omnibus (GEO) database under the accession number GSE318367.